Albumin–drug conjugates in the treatment of hepatic disorders

Bibliography

• Wade R, Whisson ME, Szekerke M. Some serum protein nitrogen mustard complexes with high chemotherapeutic selectivity. Nature 1967;215:1303-4
   PubMed Web of Science ®Google Scholar
• Busch H, Fujiwara E, Firszt DC. Studies on the metabolism of radioactive albumin in tumor-bearing rats. Cancer Res 1961;21:371-7
   PubMed Web of Science ®Google Scholar
• Cessi C, Fiume L. Increased toxicity of beta-amanitin when bound to a protein. Toxicon 1969;6:309-10
   PubMed Web of Science ®Google Scholar
• Derenzini M, Fiume L, Marinozzi V, et al. Pathogenesis of liver necrosis produced by amanitin-albumin conjugates. Lab Invest 1973;29:150-8
   PubMed Web of Science ®Google Scholar
• Barbanti Brodano G, Fiume L. Selective killing of macrophages by amanitin-albumin conjugates. Nat New Biol 1973;244:281-3
   PubMedGoogle Scholar
• Fiume L, Barbanti Brodano G. Selective toxicity of amanitin-albumin conjugates for macrophages. Experientia 1974;30:76-7
   Google Scholar
• Trouet A, Deprez De Campeneere D, De Duve C. Chemotherapy through lysosomes with a DNA-daunorubicin complex. Nat New Biol 1972;239:110-12
   PubMedGoogle Scholar
• Marinozzi V, Fiume L. Effects of alpha-amanitin on mouse and rat liver cell nuclei. Exp Cell Res 1971;67:311-22
   PubMed Web of Science ®Google Scholar
• Barbanti Brodano G, Fiume L. In vitro effect of a 5-fluorodeoxyuridine albumin conjugate on tumour cells and on peritoneal macrophages. Experientia 1974;30:1180-1
   PubMedGoogle Scholar
• Balboni PG, Minia A, Grossi MP, et al. Activity of albumin connjugates of 5-fluorodeoxyuridine and cytosine arabinoside on poxviruses as a lysosomotropic approach to antiviral chemotherapy. Nature 1976;264:181-3
   PubMed Web of Science ®Google Scholar
• Fiume L. Penetration of beta-amanitin-rabbit-albumin conjugate into hepatic parenchymal cells. Lancet 1969;2:853-4
   PubMed Web of Science ®Google Scholar
• Fiume L, Campadelli Fiume G, Wieland T. Facilitated penetration of amanitin-albumin conjugates into hepatocytes after coupling with fluorescein. Nat New Biol 1971;230:219-20
   PubMedGoogle Scholar
• Rogers JC, Kornfeld S. Hepatic uptake of proteins coupled to fetuin glycopeptide. Biochem Biophys Res Commun 1971;45:622-9
   PubMed Web of Science ®Google Scholar
• Wilson G. Effect of reductive lactosamination on the hepatic uptake of bovine pancreatic ribonuclease A dimer. J Biol Chem 1978;253:2070-2
   PubMed Web of Science ®Google Scholar
• Fiume L, Busi C, Mattioli A, et al. Hepatocyte targeting of adenine-9-beta-D-arabinofuranoside 5'-monophosphate (ara-AMP) coupled to lactosaminated albumin. FEBS Lett 1981;129:261-4
   PubMed Web of Science ®Google Scholar
• Hubbard AL, Wilson G, Ashwell G, et al. An electron microscope autoradiographic study of the carbohydrate recognition systems in rat liver. J Cell Biol 1979;83:47-64
   PubMed Web of Science ®Google Scholar
• Beljaars L, Olinga P, Molema G, et al. Characteristics of the hepatic stellate cell-selective carrier mannose 6-phosphate modified albumin (M6P28-HSA). Liver 2001;21:320-8
   PubMedGoogle Scholar
• Ashwell G, Harford J. Carbohydrate-specific receptors of the liver. Annu Rev Biochem 1982;51:531-4
   PubMed Web of Science ®Google Scholar
• Kornfeld S. Structure and function of the mannose 6-phosphate/insulin like growth factor II receptors. Annu Rev Biochem 1992;61:307-30
   PubMed Web of Science ®Google Scholar
• Greupink R, Bakker HI, Reker-Smit C, et al. Studies on the targeted delivery of the antifibrogenic compound mycophenolic acid to the hepatic stellate cell. J Hepatol 2005;43:884-92
   PubMed Web of Science ®Google Scholar
• Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 2008;132:171-83
   PubMed Web of Science ®Google Scholar
• Halloran MJ, Parker CW. The preparation of nucleotide-protein conjugates: carbodiimides as coupling agents. J Immunol 1966;96:373-8
   PubMed Web of Science ®Google Scholar
• Mims CA. The response of mice to large intravenous injections of Ectromelia virus. II. The growth of virus in the liver. Br J Exp Pathol 1959;40:543-50
   PubMed Web of Science ®Google Scholar
• Roberts JA. Histopathogenesis of mousepox: III. Ectromelia virulence. Br J Exp Pathol 1963;44:465-72
   PubMed Web of Science ®Google Scholar
• Hoare DG, Koshland DE. A method for the quantitative modification and estimation of carboxylic acid groups in proteins. J Biol Chem 1967;242:2447-53
   PubMed Web of Science ®Google Scholar
• Sheehan HA, Hlavka JJ. The cross-linking of gelatin using a water soluble carbodiimide. J Am Chem Soc 1957;79:4528-9
   Web of Science ®Google Scholar
• Fiume L, Busi C, Di Stefano G, et al. Coupling of antiviral nucleoside analogs to lactosaminated albumin by using the imidazolides of their phosphoric esters. Anal Biochem 1993;212:407-11
   PubMed Web of Science ®Google Scholar
• Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008;359:1486-500
   PubMed Web of Science ®Google Scholar
• Gray GR. The direct coupling of oligosaccharides to proteins and derivatized gels. Arch Biochem Biophys 1974;163:426-8
   PubMed Web of Science ®Google Scholar
• Schwartz BA, Gray GR. Proteins containing reductively aminated disaccharides. Synthesis and chemical characterization. Arch Biochem Biophys 1977;181:542-9
   PubMed Web of Science ®Google Scholar
• Borch RF, Bernstein MD, Durst HD. The cyanohydroborate anion as a selective reducing agent. J Am Chem Soc 1971;93:2897-904
   Web of Science ®Google Scholar
• Fiume L, Busi C, Mattioli A. Lactosaminated human serum albumin as hepatotropic drug carrier. Rate of uptake by mouse liver. FEBS Lett 1982;146:42-6
   PubMed Web of Science ®Google Scholar
• Chadwick RG, Bassendine MF, Crawford EM, et al. HBsAg-positive chronic liver disease: inhibition of DNA polymerase activity by vidarabine. Br Med J 1978;2:531-3
   PubMed Web of Science ®Google Scholar
• Pollard RB, Smith JL, Neal EA, et al. Effect of vidarabine on chronic hepatitis b virus infection. J Am Med Assoc 1978;239:1648-50
   PubMed Web of Science ®Google Scholar
• Bassendine MF, Chadwick RG, Salmeron J, et al. Adenine arabinoside therapy in HBsAg-positive chronic liver disease: a controlled study. Gastroenterology 1981;80:1016-22
   PubMed Web of Science ®Google Scholar
• Fiume L, Bassi B, Bongini A. Conjugates of 9-beta-D-arabinofuranosyladenine 5′-monophosphate (ara-AMP) with lactosaminated albumin: characterization of the drug carrier bonds. Pharm Acta Helv 1988;63:137-9
   PubMedGoogle Scholar
• Di Stefano G, Lanza M, Busi C, et al. Conjugates of nucleoside analogs with lactosaminated human albumin to selectively increase the drug levels in liver blood: requirements for a regional chemotherapy. J Pharmacol Exp Ther 2002;301:638-42
   PubMed Web of Science ®Google Scholar
• Fiume L, Mattioli A, Busi C, et al. Conjugates of adenine-9-b-D-arabinofuranoside monophosphate (ara-AMP) with lactosaminated homologous albumin are not immunogenic in the mouse. Experientia 1982;38:1087-9
   PubMedGoogle Scholar
• Fiume L, Busi C, Preti P, et al. Conjugates of ara-AMP with lactosaminated albumin: a study on their immunogenicity in mouse and rat. Cancer Drug Deliv 1987;4:145-50
   PubMedGoogle Scholar
• Torrani Cerenzia M, Fiume L, De Bernardi Venon W, et al. Adenine arabinoside monophosphate coupled to lactosaminated human albumin administered for 4 weeks in patients with chronic type B hepatitis decreased viremia without producing significant side effects. Hepatology 1996;23:657-61
   PubMed Web of Science ®Google Scholar
• Fiume L, Bassi B, Busi C, et al. Drug targeting in antiviral chemotherapy. A chemically stable conjugate of 9-beta-D-arabinofuranosyladenine 5'-monophosphate with lactosaminated albumin accomplishes a selective delivery of the drug to liver cells. Biochem Pharmacol 1986;35:967-72
   PubMed Web of Science ®Google Scholar
• Ponzetto A, Fiume L, Forzani B, et al. Adenine arabinoside monophosphate and acyclovir monophosphate coupled to lactosaminated albumin reduce woodchuck hepatitis virus viremia at doses lower than do the unconjugated drugs. Hepatology 1991;14:16-24
   PubMed Web of Science ®Google Scholar
• Fiume L, Torrani Cerenzia MR, Bonino F, et al. Inhibition of hepatitis B virus replication by vidarabine monophosphate conjugated with lactosaminated serum albumin. Lancet 1988;2:13-15
   PubMed Web of Science ®Google Scholar
• Torrani Cerenzia MR, Fiume L, Busi C, et al. Inhibition of hepatitis B virus replication by adenine arabinoside monophosphate coupled to lactosaminated albumin. Efficacy and minimal active dose. J Hepatol 1994;20:307-9
   PubMed Web of Science ®Google Scholar
• Zarski JP, Barange K, Souvignet C, et al. Efficacy and safety of lactosaminated human serum albumin-adenine arabinoside monophosphate in chronic hepatitis B patients non-responders to interferon therapy: a randomised clinical trial. J Hepatol 2001;34:487-8
   Google Scholar
• Weller IVD, Bassendine MF, Craxi A, et al. Successful treatment of HBs and HBeAg positive chronic liver disease: prolonged inhibition of viral replication by highly soluble adenine arabinoside 5'-monophosphate(ara-AMP). Gut 1982;23:717-23
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Hanson RG, Minuk GY, et al. Randomized controlled trial of adenine arabinoside monophosphate for chronic type B hepatitis. Gastroenterology 1984;86:150-7
   PubMed Web of Science ®Google Scholar
• El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-27
   PubMed Web of Science ®Google Scholar
• Wysocki PJ. Targeted therapy of hepatocellular cancer. Expert Opin Investig Drugs 2010;19:265-74
   PubMed Web of Science ®Google Scholar
• Trerè D, Fiume L, Badiali De Giorgi L, et al. The asialoglycoprotein receptor in human hepatocellular carcinomas. Its expression on the proliferating cells. Br J Cancer 1999;81:404-8
   PubMed Web of Science ®Google Scholar
• Schneider Y, Abarca J, Aboud-Pirak E, et al. Drug targeting in human cancer chemotherapy. In: Gregoriadis G, Poste G, Senior J, Trouet A, editors. Receptor mediated targeting of drugs, NATO ASI series A: life sciences. Plenum Press, New York; 1984. p. 1-25
   Google Scholar
• O'Hare KB, Hume IC, Scarlett L, et al. Effect of galactose on interaction of N-(2-hydroxypropyl) metacrylamide copolymers with hepatoma cells in culture: preliminary applications to an anticancer agent, daunomycin. Hepatology 1989;10:207-14
   PubMed Web of Science ®Google Scholar
• Seymour LW, Ulbrich K, Wedge SR, et al. N-(2-hydroxypropyl) metacrylamide copolymers targeted to the hepatocyte galactose-receptor: pharmacokinetics in DBA2 mice. Br J Cancer 1991;63:859-66
   PubMed Web of Science ®Google Scholar
• Seymour LW, Ferry DR, Anderson D, et al. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol 2002;20:1668-76
   PubMed Web of Science ®Google Scholar
• Willner D, Trail PA, Hofstead SJ, et al. (6-maleimidocaproyl)hydrazone derivative of doxorubicin – a new derivative for the preparation of immunoconjugates of doxorubicin. Bioconjug Chem 1993;4:521-7
   PubMed Web of Science ®Google Scholar
• Greenfield RS, Kaneko T, Daues A, et al. Evaluation in vitro of adriamycin immunoconjugates synthesized using an acid-sensitive hydrazone linker. Cancer Res 1990;50:6600-7
   PubMed Web of Science ®Google Scholar
• Boga C, Fiume L, Baglioni M, et al. Characterization of the conjugate of (6-maleimidocaproyl)hydrazone derivative of doxorubicin with lactosaminated human albumin by 13C NMR spectroscopy. Eur J Pharm Sci 2009;38:262-9
   PubMed Web of Science ®Google Scholar
• Di Stefano G, Lanza M, Kratz F, et al. A novel method for coupling doxorubicin to lactosaminated human albumin by an acid sensitive hydrazone bond: synthesis, characterization and preliminary biological properties of the conjugate. Eur J Pharm Sci 2004;23:393-7
   PubMed Web of Science ®Google Scholar
• Di Stefano G, Kratz F, Lanza M, et al. Doxorubicin coupled to lactosaminated human albumin remains confined within mouse liver cells after the intracellular release from the carrier. Dig Liver Dis 2003;35:428-33
   PubMedGoogle Scholar
• Di Stefano G, Fiume L, Baglioni M, et al. Doxorubicin coupled to lactosaminated albumin: effect of the heterogeneity in drug load of conjugate disposition and hepatocellular carcinoma uptake in rats. Eur J Pharm Sci 2008;33:191-8
   PubMed Web of Science ®Google Scholar
• Rajewsky MF, Dauber W, Frankenberg H. Liver carcinogenesis by diethylnitrosamine in the rat. Science 1966;152:83-5
   PubMed Web of Science ®Google Scholar
• Di Stefano G, Fiume L, Bolondi L, et al. Enhanced uptake of lactosaminated human albumin by rat hepatocarcinomas: implications for an improved chemotherapy of primary liver tumors. Liver Int 2005;25:854-60
   PubMed Web of Science ®Google Scholar
• Di Stefano G, Fiume L, Baglioni M, et al. A conjugate of doxorubicin with lactosaminated albumin enhances the drug concentrations in all the forms of rat hepatocellular carcinomas independently of their differentiation grade. Liver Int 2006;26:726-33
   PubMed Web of Science ®Google Scholar
• Di Stefano G, Fiume L, Baglioni M, et al. Coupling of lactose molecules to the carrier protein hinders the spleen and bone marrow uptake of doxorubicin conjugates with human albumin. Eur J Pharm Sci 2007;30:136-42
   PubMed Web of Science ®Google Scholar
• Fiume L, Bolondi L, Busi C, et al. Doxorubicin coupled to lactosaminated albumin inhibits the growth of hepatocellular carcinomas induced in rats by diethylnitrosamine. J Hepatol 2005;43:645-52
   PubMed Web of Science ®Google Scholar
• Di Stefano G, Fiume L, Baglioni M, et al. Efficacy of doxorubicin coupled to lactosaminated albumin on rat HCCs evaluated by ultrasound imaging. Dig Liver Dis 2008;40:278-84
   PubMedGoogle Scholar
• Di Stefano G, Fiume L, Domenicali M, et al. Doxorubicin coupled to lactosaminated albumin: effects on rats on liver fibrosis and cirrhosis. Dig Liver Dis 2006;38:404-8
   PubMedGoogle Scholar
• Di Stefano G, Derenzini M, Kratz F, et al. Liver targeted doxorubicin: effects on regenerating rat hepatocytes. Liver Int 2004;24:246-52
   PubMed Web of Science ®Google Scholar
• Fiume L, Mattioli A, Balboni PG, et al. Enhanced inhibition of virus DNA synthesis in hepatocytes by trifluorothymidine coupled to asialofetuin. FEBS Lett 1979;103:47-51
   PubMed Web of Science ®Google Scholar
• Fiume L, Busi C, Corzani S, et al. Organ distribution of a conjugate of adenine arabinoside monophosphate with lactosaminated albumin in the rat. J Hepatol 1994;20:681-2
   PubMed Web of Science ®Google Scholar
• Di Stefano G, Colonna PF, Bongini A, et al. Ribavirin conjugated with lactosaminated poly-L-lysine. Selective delivery to the liver and increased antiviral activity in mice with viral hepatitis. Biochem Pharmacol 1997;54:357-63
   PubMed Web of Science ®Google Scholar
• Di Stefano G, Busi C, Mattioli A, et al. Inhibition of [3H]thymidine incorporation into DNA of rat regenerating liver by 2′,2′-difluorodeoxycytidine coupled to lactosaminated poly-L-lysine. Biochem Pharmacol 1999;57:793-9
   PubMed Web of Science ®Google Scholar
• Di Stefano G, Busi C, Camerino A, et al. Enhanced liver blood concentrations of adenine arabinoside accomplished by lactosaminated poly-L-lysine coupling: implication for regional chemotherapy of hepatic micrometastases. Biochem Pharmacol 2000;61:457-63
   Google Scholar
• Midgley R, Kerr D. Colorectal cancer. Lancet 1999;353:391-9
   PubMed Web of Science ®Google Scholar
• Heriot AG, Kumar D. Adjuvant chemotherapy for resectable rectal and colonic cancer. Br J Surg 1998;85:300-9
   PubMed Web of Science ®Google Scholar
• MacDonald JS, Astrow AB. Adjuvant chemotherapy of colon cancer. Semin Oncol 2001;28:30-40
   PubMed Web of Science ®Google Scholar
• van Laar JAM, Rustum YM, Ackland SP, et al. Comparison of 5-fluoro-2'-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer. Eur J Cancer 1998;34:296-306
   PubMed Web of Science ®Google Scholar
• Ensminger WD, Rosowsky A, Raso V, et al. A clinical-pharmacological evaluation of hepatic arterial infusion of 5-fluoro-2'-deoxyuridine and 5-fluorouracil. Cancer Res 1978;38:3784-92
   PubMed Web of Science ®Google Scholar
• Wagner JG, Gyves JW, Stetson PL, et al. Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients. Cancer Res 1986;46:1499-506
   PubMed Web of Science ®Google Scholar
• Di Stefano G, Busi C, Fiume L. Fluoxuridine coupling with lactosaminated human albumin to increase the drug efficacy on liver micrometastases. Dig Liver Dis 2002;34:439-46
   PubMedGoogle Scholar
• Di Stefano G, Tubaro M, Lanza M, et al. Synthesis and physicochemical characteristics of a liver-targeted conjugate of fluorodeoxyuridine monophosphate with lactosaminated human albumin. Rapid Commun Mass Spectrom 2003;17:2503-7
   PubMed Web of Science ®Google Scholar
• Taylor I, Machin D, Mullee M, et al. A randomised controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer. Br J Surg 1985;72:359-63
   PubMed Web of Science ®Google Scholar
• Fielding RP, Hittinger R, Grace RH, et al. Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma. Lancet 1992;340:502-6
   PubMed Web of Science ®Google Scholar
• Rougier P, Sahmoud T, Nitti D, et al. Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. Lancet 1998;351:1677-81
   PubMed Web of Science ®Google Scholar
• Liver Infusion Meta-analysis Group. Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. J Natl Cancer Inst 1997;89:497-505
   PubMed Web of Science ®Google Scholar
• Hohn DC, Melnick J, Stagg R, et al. Biliary sclerosis in patients receiving hepatic arterial infusion of floxuridine. J Clin Oncol 1985;3:98-102
   PubMed Web of Science ®Google Scholar
• Kemeny N, Seiter K, Niedzwiecki D, et al. A randomized trial of hepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer 1992;69:327-34
   PubMed Web of Science ®Google Scholar
• Andrews JC, Kunsten C, Terio P, et al. Hepatobiliary toxicity of 5-fluoro-2'-deoxyuridine. Intra-arterial versus portal venous routes of infusion. Invest Radiol 1991;26:461-4
   PubMed Web of Science ®Google Scholar
• Mitra SK. The terminal distribution of hepatic artery with special reference to arterio-portal anastomosis. J Anat 1966;100:651-63
   PubMed Web of Science ®Google Scholar
• Rappaport AM. The microcirculatory hepatic unit. Microvasc Res 1973;6:212-38
   PubMed Web of Science ®Google Scholar
• Cho KJ, Lunderquist A. The peribiliary vascular plexus: the microvascular architecture of the bile duct in the rabbit and in clinical cases. Radiology 1983;147:357-64
   PubMed Web of Science ®Google Scholar
• Hautekeete ML, Geerts A. The hepatic stellate (Ito) cell: its role in human liver disease. Virchows Arch 1997;430:195-207
   PubMed Web of Science ®Google Scholar
• De Bleser PJ, Jannes P, van Buul-Offers SC, et al. Insulinlike growth factor-II/mannose 6-phosphate receptor is expressed on CCl4-exposed rat fat-storing cells and facilitates activation of latent transforming growth factor-beta in cocultures with sinusoidal endothelial cells. Hepatology 1995;21:1429-37
   PubMed Web of Science ®Google Scholar
• Ghosh P, Dahms NM, Kornfeld S. Mannose 6-phosphate receptors: new twists in the tale. Nat Rev Mol Cell Biol 2003;4:202-12
   PubMed Web of Science ®Google Scholar
• Beljaars L, Molema G, Weert B, et al. Albumin modified with mannose 6-phosphate: a potential carrier for selective delivery of antifibrotic drugs to rat and human hepatic stellate cells. Hepatology 1999;29:1486-93
   PubMed Web of Science ®Google Scholar
• Roche AC, Midoux P, Bouchard P, et al. Membrane lectins on human monocytes. Maturation-dependent modulation of 6-phosphamannose and mannose receptors. FEBS Lett 1985;193:63-8
   PubMed Web of Science ®Google Scholar
• Monsigny M, Roche AC, Midoux P. Uptake of neoglycoproteins via membrane lectin(s) of L1210 cells evidenced by quantitative cytofluorometry and drug targeting. Biol Cell 1984;51:187-96
   PubMed Web of Science ®Google Scholar
• Kataoka M, Tavassoli M. Synthetic neoglycoproteins: a class of reagents for detection of sugar-recognizing substances. J Histochem Cytochem 1984;32:1091-4
   PubMed Web of Science ®Google Scholar
• Moreno M, Gonzalo T, Kok RJ, et al. Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats. Hepatology 2010;51:942-52
   PubMed Web of Science ®Google Scholar
• Temming K, Fretz M, Kok RJ. Organ- and cell-type specific delivery of kinase inhibitors: a novel approach in the development of targeted drugs. Curr Mol Pharmacol 2008;1:1-12
   PubMedGoogle Scholar
• van Beuge MM, Prakash J, Lacombe M, et al. Reduction of fibrogenesis by selective delivery of a Rho kinase inhibitor to hepatic stellate cells in mice. J Pharmacol Exp Ther 2011;337:628-35
   PubMed Web of Science ®Google Scholar
• Poelstra K, Prakash J, Beljaars L. Drug targeting to the diseased liver. J Control Release 2012;161:188-97
   PubMed Web of Science ®Google Scholar
• Melgert B, Olinga P, van der Laan JMS, et al. Targeting dexamethasone to Kupffer cells: effects on liver inflammation and fibrosis in rats. Hepatology 2001;34:719-28
   PubMed Web of Science ®Google Scholar
• Beljaars L, Poelstra K, Molema G, et al. Targeting of sugar- and charge-modified albumins to fibrotic rat livers: the accessibility of hepatic cells after chronic bile duct ligation. J Hepatol 1998;29:579-88
   PubMed Web of Science ®Google Scholar
• Fiume L, Chiricolo M, Busi C, et al. A conjugate of prednisolone with albumin is pharmacologically active in macrophages. Pharm Acta Helv 1989;64:351-2
   PubMedGoogle Scholar
• Fiume L, Bassi B, Busi C, et al. Galactosylated poly(L-Lysine) as a hepatotropic carrier of 9-beta-D-arabinofuranosyladenine 5'-monophosphate. FEBS Lett 1986;203:203-6
   PubMed Web of Science ®Google Scholar
• Di Stefano G, Busi C, Mattioli A, et al. Selective delivery to the liver of antiviral nucleoside analogs coupled to a high molecular mass lactosaminated poly-L-lysine and administered to mice by intramuscular route. Biochem Pharmacol 1995;49:1769-75
   PubMed Web of Science ®Google Scholar
• Rensen PC, van Dijk MC, Havenaar EC, et al. Selective liver targeting of antivirals by recombinant chylomicrons – a new therapeutic approach to hepatitis B. Nat Med 1995;1:221-5
   PubMed Web of Science ®Google Scholar
• Enriquez PM, Jung C, Josephson L, et al. Conjugation of adenine arabinoside 5'-monophosphate to arabinogalactan: synthesis, characterization, and antiviral activity. Bioconjug Chem 1995;6:195-202
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Saltz LB. Doxorubicin and sorafenib for treatment of advanced hepatocellular cancer. Gastroenterology 2011;141:e19-20
   Google Scholar
• Rytelewski M, Ferguson PJ, Vareki SM, et al. Inhibition of BRCA2 and thymidilate synthase creates multidrug sensitive tumor cells via the induction of combined “complementary lethality”. Mol Ther Nucleic Acids 2013;2:e78
   PubMedGoogle Scholar
• Meike S, Yamamori T, Yasui H, et al. A nucleoside anticancer drug, 1-(3-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (TAS106), sensitizes cells to radiation by suppressing BRCA2 expression. Mol Cancer 2011;10:92
   PubMed Web of Science ®Google Scholar
• Huddleston JE. DNA repair: BRCA2 gets protective at forks Nat Rev Mol Cell Biol 2011;12:400
   Google Scholar
• Doyle JS, Aspinall E, Liew D, et al. Current and emerging antiviral treatment for hepatitis C infection. Br J Clin Pharmacol 2012;75:931-43
   Web of Science ®Google Scholar
• Fletcher SP, Delaney WE. New therapeutic targets and drugs for the treatment of chronic hepatitis B. Semin Liver Dis 2013;33:130-7
   PubMed Web of Science ®Google Scholar
• Cai D, Mills C, Yu W, et al. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother 2012;56:4277-88
   PubMed Web of Science ®Google Scholar
• Zhao W, Zhang L, Xu Y, et al. Hepatic stellate cells promote tumor progression by enhancement of immunosuppressive cells in an orthotopic liver tumor mouse model. Lab Invest 2014;94:182-91
   PubMed Web of Science ®Google Scholar
• Faulstich H, Fiume L. Protein conjugates of fungal toxins. Methods Enzymol 1985;112:225-37
   PubMed Web of Science ®Google Scholar
• Hovorka O, St'astny M, Etrych T, et al. Differences in the intracellular fate of free and polymer-bound doxorubicin. J Control Release 2002;80:101-17
   PubMed Web of Science ®Google Scholar
• Fiume L, Betts CM, Busi C, et al. The pathogenesis of vacuoles produced in rat and mouse liver cells by a conjugate of adenine arabinoside monophosphate with lactosaminated albumin. J Hepatol 1992;15:314-22
   PubMed Web of Science ®Google Scholar
• Ensminger WD, Gyves JW. Regional Chemotherapy of neoplastic diseases. Pharmacol Ther 1983;21:277-93
   PubMed Web of Science ®Google Scholar
• Fiume L, Baglioni M, Bolondi L, et al. Doxorubicin coupled to lactosaminated human albumin: a hepatocellular carcinoma targeted drug. Drug Discov Today 2008;13:1002-9
   PubMed Web of Science ®Google Scholar
• Fiume L, Di Stefano G. Lactosaminated human albumin, a hepatotropic carrier of drugs. Eur J Pharm Sci 2010;40:253-62
   PubMed Web of Science ®Google Scholar